Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mayo Clinic Laboratories, |
RCV004791078 | SCV005413344 | likely pathogenic | not provided | 2024-02-14 | criteria provided, single submitter | clinical testing | PP3, PP4, PM1, PM2_moderate, PM5 |
Athena Diagnostics | RCV004791078 | SCV005620733 | pathogenic | not provided | 2024-08-20 | criteria provided, single submitter | clinical testing | This variant alters a critical location within the protein, and is expected to severely affect function and cause disease. This variant has not been reported in large, multi-ethnic general populations. (http://gnomad.broadinstitute.org) This variant has been identified in at least one individual with clinical features associated with CADASIL. Greater than 90% of NOTCH3 pathogenic variants associated with CADASIL involve the gain or loss of a cysteine residue within the epidermal growth factor (EGF)-like repeat domain (PMID: 32457593, 20301673). |